Cancer Conversations on the Expanding Therapeutic Landscape for CDK4/6 Inhibitors in HR-Positive/HER2-Negative Breast Cancer

Learn more about the evolving role of CDK4/6 inhibitors to treat patients with HR-positive/HER2-negative breast cancer through a certified on-demand webcast, downloadable self-teaching slideset, and podcast.

Share

Program Content

No activities added yet

No activities added yet

No activities added yet

No activities added yet

Provided by

ProCE Banner

Provided by Clinical Care Options, LLC

Supporters

Supported by educational grants from Lilly and Novartis Pharmaceuticals Corporation.

Lilly

Novartis Pharmaceuticals Corporation